Results 121 to 130 of about 6,916,201 (263)
HOXC11 drives colorectal cancer progression by transcriptionally activating CAMK2A, which triggers NF‐κB–dependent CXCL5 upregulation. CXCL5–CXCR2 signaling further reinforces HOXC11 expression through the ERK1/2–SP1 axis, forming a prometastatic positive feedback loop that is effectively disrupted by combined CAMK2A and CXCR2 inhibition.
Qingyang Sun +12 more
wiley +1 more source
Androgen receptor (AR) drives copper accumulation in prostate cancer while inducing MTF1 to buffer copper toxicity. EP300‐mediated lactylation of MTF1 at K218 promotes its nuclear translocation and metallothionein expression, sequestering cytosolic copper and preventing mitochondrial cuproptosis.
Kai Li +21 more
wiley +1 more source
While most ovarian cancer (OC) patients respond to front-line platinum/taxane chemotherapy and surgical debulking, the majority will develop platinum-resistance and recur.
Parisa Nikeghbal +5 more
doaj +1 more source
Persistent or recurrent retinoblastoma (RB) is associated with the presence of vitreous or/and subretinal seeds in advanced RB and represents a major cause of therapeutic failure.
Duangporn Saengwimol +9 more
doaj +1 more source
Single‐cell, spatial, molecular, and pathology analyses identify a CDH3‐associated malignant epithelial state in thymic epithelial tumors. This state links stem‐like and EMT programs to M2 macrophage–rich immunosuppressive niches, genomic instability, poor survival, and drug vulnerability.
Yuntao Feng +13 more
wiley +1 more source
Irradiation dose response curves of organoids: data for Patient-derived organoids predict chemoradiation responses of locally advanced rectal ...
Yao, Y (via Mendeley Data), Yao, Ye
core +1 more source
A schematic illustrating the fabrication process and ferroptosis‐mediated therapeutic mechanism of carrier‐free self‐assembled BBR/NC‐SAPs for overcoming bortezomib resistance in multiple myeloma. ABSTRACT Therapeutic relapse driven by bortezomib resistance represents a formidable clinical barrier in the management of multiple myeloma (MM).
Yiwen Lv +16 more
wiley +1 more source
Characteristics of patient-derived prostate cancer organoids.
(A) Percentage of organoids with loss of the chromosome Y (left) and Yq (right). (B) Doubling times of organoids. (C) Breakdown of organoids, stratified by type of prostate cancer tissue used for patient-derived organoid development and Y chromosome ...
Kalyani Chadalavada (8990516) +9 more
core +1 more source
Lactate accumulation in glioblastoma drives lactylation of STING at lysine 370, a primate‐conserved residue. K370 lactylation weakens STING‐TBK1 binding, destabilizes STING, and disrupts ER‐to‐Golgi trafficking, blunting type I interferon signaling. LDHA inhibition reverses K370 lactylation and improves the antitumor efficacy of STING agonism combined ...
Yueyao Wu +11 more
wiley +1 more source
A systematic review of patient-derived tumor organoids generation from malignant effusions
This review assesses the possibility of utilizing malignant effusions (MEs) for generating patient-derived tumor organoids (PDTOs). Obtained through minimally invasive procedures MEs broaden the spectrum of organoid sources beyond resection specimens and tissue biopsies.
Sofie Seghers +8 more
openaire +3 more sources

